Immuneering Corporation

Immuneering Corporation is a late-stage oncology company focused on developing medicines for broad populations of cancer patients in the United States. Its lead product candidate is IMM-1-104 (atebimetinib), a dual-MEK inhibitor currently in a Phase 3 clinical trial for cancers including pancreatic and non-small cell lung cancer caused by RAS or RAF mutations. The company also has IMM-6-415 (envometinib) in a Phase 1/2a trial for solid tumors, along with multiple deep cyclic inhibitor discovery programs. Immuneering has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo for RAS-mutant non-small cell lung cancer, and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib for KRAS G12C-mutant non-small cell lung cancer.

Immuneering Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol IMRX. The company's stock is traded in US Dollars (USD), which is the standard currency for equities listed on US exchanges. As a US-based company, its financial reporting and stock transactions are conducted in USD, making it accessible to investors trading on US markets.

Immuneering Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer, leveraging its expertise in oncology to create treatments that target specific genetic mutations. The company's work in dual-MEK inhibition and deep cyclic inhibitors places it at the forefront of precision medicine, addressing unmet medical needs in cancers such as pancreatic and non-small cell lung cancer.

Immuneering Corporation is headquartered in Cambridge, Massachusetts, United States. The company was incorporated in 2008, giving it over a decade of experience in oncology drug development. Cambridge is a major hub for biotechnology and pharmaceutical research, providing Immuneering with access to a rich ecosystem of scientific talent, research institutions, and potential partners. The company's location supports its mission to develop treatments for cancer patients, particularly those with RAS or RAF mutations.

Immuneering Corporation generates value by developing and advancing a pipeline of oncology therapies through clinical trials, with the goal of obtaining regulatory approval and commercializing them. Its business model relies on strategic partnerships, as evidenced by clinical supply agreements with Regeneron Pharmaceuticals and Eli Lilly and Company to evaluate its lead candidate atebimetinib in combination with other drugs. These collaborations help share development costs and expand the potential of its therapies. The company's focus on dual-MEK inhibition and deep cyclic inhibitors targets specific cancer mutations, aiming to address large patient populations and create significant therapeutic value.